The Dangers of America's Nicotine Boom

How the tobacco industry rebranded a brutally addictive drug from deadly to desirable—and what it means for our health.
Pharmaceutical Technology

JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff

At JPM26, MSD noted it was awaiting 20 potential launches and 80 late-stage readouts, which it claims could double $35bn ...
Le Lézard

FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced its ...